NCT05873062View on ClinicalTrials.gov

Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 12, 2023

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions
Myoclonus Epilepsies, Progressive
Interventions
DRUG

AUT00201

Single oral dose

DRUG

Placebo

Single oral dose

Trial Locations (1)

19104

University of Pennsylvania, Penn Epilepsy Center, Philadelphia

Sponsors
All Listed Sponsors
lead

Autifony Therapeutics Limited

INDUSTRY

NCT05873062 - Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK | Biotech Hunter | Biotech Hunter